Clinical Trials
3 trialsNCT05445778 2026-06-02
GLORIOSA
AbbVie
Phase 3 Active not recruiting
NCT05041257 2026-01-09
PICCOLO
AbbVie
Phase 2 Completed
NCT05456685 2025-10-28
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
AbbVie
Phase 2 Active not recruiting